Androgen deprivation therapy is a lifesaving therapy used by thousands of men each year, but some patients are warning of ...

In this article, Sandy Srinivas, MD, discusses androgen deprivation therapy as a treatment for advanced prostate cancer and examines potential avenues for future research, ...

Androgen deprivation therapy was associated with a 72 percent higher risk of heart failure in a study of patients with prostate cancer. In The Journal of Clinical Pharmacology study, incidence ...

Androgen-deprivation therapy (ADT) is well established as the standard of care in metastatic prostate cancer (PCa) management; however, ADT has significant adverse effects (AEs) that must be ...

EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission ...

Among patients with metastatic hormone-sensitive prostate cancer, the treatment combination of Nubeqa (darolutamide) and androgen deprivation therapy (ADT) has reportedly displayed positive results ...

The effectiveness of primary androgen-deprivation therapy (PADT) for clinically localized prostate cancer has been found lacking. A retrospective cohort study of more than 15,000 men newly ...

A meta-analysis showed risk for heart failure in men with prostate cancer receiving ADT was higher in Asian studies that in North American studies.

Time to Benefit of Androgen Deprivation Therapy in Patients With Localized Prostate Cancer Undergoing Radiotherapy. JCO Precis Oncol 9 , e2400605 (2025). DOI: 10.1200/PO-24-00605 ...

Purpose The potential association between androgen deprivation therapy (ADT) and cardiovascular mortality (CVM) remains controversial. This study assessed mortality outcomes in a large national ...